3mro
From Proteopedia
(Difference between revisions)
Line 2: | Line 2: | ||
<StructureSection load='3mro' size='340' side='right' caption='[[3mro]], [[Resolution|resolution]] 2.35Å' scene=''> | <StructureSection load='3mro' size='340' side='right' caption='[[3mro]], [[Resolution|resolution]] 2.35Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3mro]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[3mro]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3MRO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3MRO FirstGlance]. <br> |
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3mr9|3mr9]], [[3mrb|3mrb]], [[3mrc|3mrc]], [[3mrd|3mrd]], [[3mre|3mre]], [[3mrf|3mrf]], [[3mrg|3mrg]], [[3mrh|3mrh]], [[3mri|3mri]], [[3mrj|3mrj]], [[3mrk|3mrk]], [[3mrl|3mrl]], [[3mrm|3mrm]], [[3mrn|3mrn]], [[3mrp|3mrp]], [[3mrq|3mrq]], [[3mrr|3mrr]], [[3gsn|3gsn]], [[3gso|3gso]], [[3gsq|3gsq]], [[3gsr|3gsr]], [[3gsu|3gsu]], [[3gsv|3gsv]], [[3gsw|3gsw]], [[3gsx|3gsx]]</td></tr> | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3mr9|3mr9]], [[3mrb|3mrb]], [[3mrc|3mrc]], [[3mrd|3mrd]], [[3mre|3mre]], [[3mrf|3mrf]], [[3mrg|3mrg]], [[3mrh|3mrh]], [[3mri|3mri]], [[3mrj|3mrj]], [[3mrk|3mrk]], [[3mrl|3mrl]], [[3mrm|3mrm]], [[3mrn|3mrn]], [[3mrp|3mrp]], [[3mrq|3mrq]], [[3mrr|3mrr]], [[3gsn|3gsn]], [[3gso|3gso]], [[3gsq|3gsq]], [[3gsr|3gsr]], [[3gsu|3gsu]], [[3gsv|3gsv]], [[3gsw|3gsw]], [[3gsx|3gsx]]</td></tr> | ||
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HLA, HLA-A, HLAA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HLA, HLA-A, HLAA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, BETA-2 MICROGLUBULIN, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> |
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3mro FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3mro OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3mro RCSB], [http://www.ebi.ac.uk/pdbsum/3mro PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3mro FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3mro OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3mro RCSB], [http://www.ebi.ac.uk/pdbsum/3mro PDBsum]</span></td></tr> | ||
</table> | </table> | ||
Line 11: | Line 11: | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/1A02_HUMAN 1A02_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/MAR1_HUMAN MAR1_HUMAN]] Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.<ref>PMID:15695812</ref> <ref>PMID:19717472</ref> [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. | [[http://www.uniprot.org/uniprot/1A02_HUMAN 1A02_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/MAR1_HUMAN MAR1_HUMAN]] Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.<ref>PMID:15695812</ref> <ref>PMID:19717472</ref> [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The structural rules governing peptide/MHC (pMHC) recognition by T cells remain unclear. To address this question, we performed a structural characterization of several HLA-A2/peptide complexes and assessed in parallel their antigenicity, by analyzing the frequency of the corresponding Ag-specific naive T cells in A2(+) and A2(-) individuals, as well as within CD4(+) and CD8(+) subsets. We were able to find a correlation between specific naive T cell frequency and peptide solvent accessibility and/or mobility for a subset of moderately prominent peptides. However, one single structural parameter of the pMHC complexes could not be identified to explain each peptide antigenicity. Enhanced pMHC antigenicity was associated with both highly biased TRAV usage, possibly reflecting favored interaction between particular pMHC complexes and germline TRAV loops, and peptide structural features allowing interactions with a broad range of permissive CDR3 loops. In this context of constrained TCR docking mode, an optimal peptide solvent exposed surface leading to an optimal complementarity with TCR interface may constitute one of the key features leading to high frequency of specific T cells. Altogether our results suggest that frequency of specific T cells depends on the fine-tuning of several parameters, the structural determinants governing TCR-pMHC interaction being just one of them. | ||
+ | |||
+ | Analysis of relationships between peptide/MHC structural features and naive T cell frequency in humans.,Reiser JB, Legoux F, Gras S, Trudel E, Chouquet A, Leger A, Le Gorrec M, Machillot P, Bonneville M, Saulquin X, Housset D J Immunol. 2014 Dec 15;193(12):5816-26. doi: 10.4049/jimmunol.1303084. Epub 2014 , Nov 12. PMID:25392532<ref>PMID:25392532</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
==See Also== | ==See Also== | ||
Line 19: | Line 27: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Human]] |
[[Category: Bonneville, M]] | [[Category: Bonneville, M]] | ||
[[Category: Chouquet, A]] | [[Category: Chouquet, A]] |
Revision as of 10:59, 28 January 2015
Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant
|
Categories: Human | Bonneville, M | Chouquet, A | Debeaupuis, E | Echasserieau, K | Gorrec, M Le | Housset, D | Reiser, J B | Saulquin, X | Decapeptide | Hla | Immune response | Immune system | Mart1 | Melan-a | Mhc class i | Tumoral peptide